top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Frame 1410148109.png
Frame 100000825.png
Frame i1000008267.png
Frame 1410148108.png
Frame 10000082699.png
Fra 1000008266.png
Frame 1000i008268.png
Frame 1410148110.png
Frame 100070.png
Frame 1410148111.png
valve.png

One Scan. All These Reports.

From Calcium Scoring and Lung Screening to Comprehensive Health Insights - with AI.

Myosteatosis:
Muscle Quality as a New Cardiometabolic Biomarker

Myosteatosis, characterized by fat infiltration into skeletal muscle, is an emerging biomarker of systemic metabolic dysfunction. AI-driven measurement of thoracic skeletal muscle density from CAC scans has shown strong predictive value for HF, AF, CHD), and all-cause mortality. Recent studies demonstrate that combining myosteatosis with CAC scores amplifies risk prediction, particularly for males, making it a critical addition to AI-CVD®.

Thoracic-Aortic-Calcification_Illustration.png
05_HeartLung_AI-CVD-diagram-1.5_Thoracic-Aortic-Calcification_2X_E.jpg
05_HeartLung_AI-CVD-diagram-1.5_Thoracic-Aortic-Calcification_2X_E.jpg
05_HeartLung_AI-CVD-diagram-1.5_Thoracic-Aortic-Calcification_2X_E.jpg

Enhanced Risk Stratification with AI-CVD®

HeartLung's AI-CVD® utilizes advanced AI algorithms to measure thoracic skeletal muscle density from CAC scans. This data, when combined with CAC scores, enhances the predictive accuracy for various cardiovascular conditions, particularly in males. The comprehensive evaluation provided by AI-CVD® enables early intervention and personalized treatment plans, helping to manage and mitigate the risks associated with myosteatosis and systemic metabolic dysfunction.

AI-CVD™ Emphysema Index on 5800 MESA Cases: RUL (Right Upper Lobe)

Clinical Implications of Myosteatosis

Myosteatosis involves the infiltration of fat into skeletal muscle, which can significantly impact muscle function and overall metabolic health. This condition is associated with systemic metabolic dysfunction, increasing the risk of heart failure, atrial fibrillation, coronary heart disease, and all-cause mortality. By incorporating myosteatosis measurements into HeartLung's AI-CVD® assessments, healthcare professionals can gain a deeper understanding of a patient's cardiometabolic health.

AI-CVD_Figure-14_Emphysema_3.png
AI-CVD_Figure-14_Emphysema_2.png
  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png
iScreen Shoter - 20261104171348520.jpg

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page